Smartphone-powered iontophoresis-microneedle array patch for controlled transdermal delivery.
Bionanoelectronics
Engineering
Journal
Microsystems & nanoengineering
ISSN: 2055-7434
Titre abrégé: Microsyst Nanoeng
Pays: England
ID NLM: 101695458
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
06
2020
revised:
03
10
2020
accepted:
26
10
2020
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
The incidence rate of diabetes has been increasing every year in nearly all nations and regions. The traditional control of diabetes using transdermal insulin delivery by metal needles is generally associated with pain and potential infections. While microneedle arrays (MAs) have emerged as painless delivery techniques, the integration of MA systems with electronic devices to precisely control drug delivery has rarely been realized. In this study, we developed an iontophoresis-microneedle array patch (IMAP) powered by a portable smartphone for the active and controllable transdermal delivery of insulin. The IMAP in situ integrates iontophoresis and charged nanovesicles into one patch, achieving a one-step drug administration strategy of "penetration, diffusion and iontophoresis". The MA of the IMAP is first pressed on the skin to create microholes and then is retracted, followed by the iontophoresis delivery of insulin-loaded nanovesicles through these microholes in an electrically controlled manner. This method has synergistically and remarkably enhanced controlled insulin delivery. The amount of insulin can be effectively regulated by the IMAP by applying different current intensities. This in vivo study has demonstrated that the IMAP effectively delivers insulin and produces robust hypoglycemic effects in a type-1 diabetic rat model, with more advanced controllability and efficiency than delivery by a pristine microneedle or iontophoresis. The IMAP system shows high potential for diabetes therapy and the capacity to provide active as well as long-term glycemic regulation without medical staff care.
Identifiants
pubmed: 34567719
doi: 10.1038/s41378-020-00224-z
pii: 224
pmc: PMC8433361
doi:
Types de publication
Journal Article
Langues
eng
Pagination
112Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interest.
Références
Nanomedicine. 2012 Feb;8(2):221-7
pubmed: 21703994
Mater Sci Eng C Mater Biol Appl. 2016 Aug 1;65:135-42
pubmed: 27157736
J Control Release. 2018 Sep 28;286:201-209
pubmed: 30056119
J Control Release. 2009 Oct 1;139(1):63-72
pubmed: 19481577
Australas J Dermatol. 2020 May;61(2):140-146
pubmed: 31944270
ACS Appl Mater Interfaces. 2018 Oct 3;10(39):33060-33069
pubmed: 30204401
Adv Mater. 2016 Apr;28(16):3115-3121
pubmed: 26928976
J Control Release. 2014 Nov 10;193:257-69
pubmed: 24801250
Int J Pharm. 2014 Sep 10;472(1-2):65-73
pubmed: 24877757
J Drug Target. 2013 May;21(4):354-66
pubmed: 23311703
Lancet. 2001 Sep 1;358(9283):739-46
pubmed: 11551598
Drug Deliv. 2018 Nov;25(1):1728-1739
pubmed: 30182757
Drug Dev Ind Pharm. 2015;41(12):1962-7
pubmed: 25758411
Int J Pharm. 2004 Apr 15;274(1-2):185-90
pubmed: 15072794
Int J Pharm. 2015 Nov 10;495(1):318-328
pubmed: 26325320
Acta Biomater. 2013 Nov;9(11):8952-61
pubmed: 23816646
Nat Commun. 2017 Nov 24;8(1):1777
pubmed: 29176623
Mater Sci Eng C Mater Biol Appl. 2018 Sep 1;90:180-188
pubmed: 29853081
J Control Release. 2017 Apr 10;251:11-23
pubmed: 28215667
Mater Sci Eng C Mater Biol Appl. 2017 Nov 1;80:187-196
pubmed: 28866156
Int J Pharm. 2012 Sep 15;434(1-2):106-14
pubmed: 22633929
Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:725-734
pubmed: 27987766
Sci Transl Med. 2019 Jul 31;11(503):
pubmed: 31366579
JAMA. 1997 Nov 26;278(20):1663-9
pubmed: 9388085
J Control Release. 2012 Apr 10;159(1):52-9
pubmed: 22265694
ACS Nano. 2017 Jan 24;11(1):395-406
pubmed: 28001346
ACS Nano. 2018 Mar 27;12(3):2466-2473
pubmed: 29455516
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8260-5
pubmed: 26100900
Int J Pharm. 2009 Aug 13;378(1-2):93-100
pubmed: 19501142
Nat Nanotechnol. 2016 Jun;11(6):566-572
pubmed: 26999482
Nat Biomed Eng. 2019 Mar;3(3):220-229
pubmed: 30948808
ACS Appl Mater Interfaces. 2018 Mar 21;10(11):9247-9256
pubmed: 29493217
J Control Release. 2019 Nov 28;314:72-80
pubmed: 31629710
J Control Release. 2017 Nov 10;265:93-101
pubmed: 29037785
Int J Pharm. 2020 Feb 25;576:118991
pubmed: 31884059
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
J Control Release. 2012 Nov 28;164(1):26-40
pubmed: 23064010
Adv Drug Deliv Rev. 2019 Jan 15;139:51-70
pubmed: 30528729
Adv Drug Deliv Rev. 2018 Mar 1;127:58-84
pubmed: 29425769
Diabetes Res Clin Pract. 1995 May;28(2):103-17
pubmed: 7587918
Adv Drug Deliv Rev. 2014 Jun;73:63-82
pubmed: 24333231